We further confirmed the presence of myeloid_MKI67 cells in a dataset collating hormone receptor-positive and triple-negative breast cancers from patients who received neoadjuvant therapy with anti-PD1 antibodies46 (Figure 8G). Here, NR4A1 is linked to triple-negative breast carcinoma.